PortalPublikationenAllogeneic stem-cell transplantation with sequential conditi...

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party

Standard

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. / Bazarbachi, Abdul Hamid; Al Hamed, Rama; Labopin, Myriam; Afanasyev, Boris; Hamladji, Rose-Marie; Beelen, Dietrich; Eder, Matthias; Scheid, Christof; Wu, Depei; Bunjes, Donald; Stepensky, Polina; Tischer, Johanna; Kröger, Nicolaus; Peric, Zina; Aljurf, Mahmoud; Giebel, Sebastian; Nagler, Arnon; Mohty, Mohamad.

in: BONE MARROW TRANSPL, Jahrgang 55, Nr. 3, 03.2020, S. 595-602.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bazarbachi, AH, Al Hamed, R, Labopin, M, Afanasyev, B, Hamladji, R-M, Beelen, D, Eder, M, Scheid, C, Wu, D, Bunjes, D, Stepensky, P, Tischer, J, Kröger, N, Peric, Z, Aljurf, M, Giebel, S, Nagler, A & Mohty, M 2020, 'Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party', BONE MARROW TRANSPL, Jg. 55, Nr. 3, S. 595-602. https://doi.org/10.1038/s41409-019-0702-2

APA

Bazarbachi, A. H., Al Hamed, R., Labopin, M., Afanasyev, B., Hamladji, R-M., Beelen, D., Eder, M., Scheid, C., Wu, D., Bunjes, D., Stepensky, P., Tischer, J., Kröger, N., Peric, Z., Aljurf, M., Giebel, S., Nagler, A., & Mohty, M. (2020). Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. BONE MARROW TRANSPL, 55(3), 595-602. https://doi.org/10.1038/s41409-019-0702-2

Vancouver

Bazarbachi AH, Al Hamed R, Labopin M, Afanasyev B, Hamladji R-M, Beelen D et al. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. BONE MARROW TRANSPL. 2020 Mär;55(3):595-602. https://doi.org/10.1038/s41409-019-0702-2

Bibtex

@article{f5f2f8fc2f3143c6b8c7ceaa6c20b49e,
title = "Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party",
abstract = "Treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) remains a clinical challenge with generally dismal prognosis. Allogeneic stem-cell transplantation using sequential conditioning ({"}FLAMSA{"}-like) has shown promising results in relapsed/refractory acute myeloid leukemia, but little is known about its efficacy in RR-ALL. We identified 115 patients (19-66 years) with relapsed (74%) or primary-refractory (26%) ALL allografted from matched related (31%), matched unrelated (58%), or haploidentical donor (11%). Median follow-up was 37 (13-111) months. At day 100, cumulative incidences of grade II-IV/III-IV acute graft-versus-host-disease (GVHD) were 30% and 17%, respectively. Two-year cumulative incidence of chronic GVHD was 25% with 11% extensive cases. Two-year relapse incidence (RI) was 45%, non-relapse mortality was 41%. Two-year leukemia free survival (LFS) was 14%, overall survival (OS) 17%, and GVHD relapse-free survival (GRFS) was 14%. In multivariable analysis, Karnofsky score <90 negatively affected RI, LFS, OS, and GRFS. Conditioning with chemotherapy alone, compared with total body irradiation (TBI) negatively affected RI (HR = 3.3; p = 0.008), LFS (HR = 1.94; p = 0.03), and OS (HR = 2.0; p = 0.03). These patients still face extremely poor outcomes, highlighting the importance of incorporating novel therapies (e.g., BITE antibodies, inotuzumab, CAR-T cells). Nevertheless, patients with RR-T-cell ALL remain with an unmet treatment need, for which TBI-based sequential conditioning could be one of few available options.",
author = "Bazarbachi, {Abdul Hamid} and {Al Hamed}, Rama and Myriam Labopin and Boris Afanasyev and Rose-Marie Hamladji and Dietrich Beelen and Matthias Eder and Christof Scheid and Depei Wu and Donald Bunjes and Polina Stepensky and Johanna Tischer and Nicolaus Kr{\"o}ger and Zina Peric and Mahmoud Aljurf and Sebastian Giebel and Arnon Nagler and Mohamad Mohty",
year = "2020",
month = mar,
doi = "10.1038/s41409-019-0702-2",
language = "English",
volume = "55",
pages = "595--602",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party

AU - Bazarbachi, Abdul Hamid

AU - Al Hamed, Rama

AU - Labopin, Myriam

AU - Afanasyev, Boris

AU - Hamladji, Rose-Marie

AU - Beelen, Dietrich

AU - Eder, Matthias

AU - Scheid, Christof

AU - Wu, Depei

AU - Bunjes, Donald

AU - Stepensky, Polina

AU - Tischer, Johanna

AU - Kröger, Nicolaus

AU - Peric, Zina

AU - Aljurf, Mahmoud

AU - Giebel, Sebastian

AU - Nagler, Arnon

AU - Mohty, Mohamad

PY - 2020/3

Y1 - 2020/3

N2 - Treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) remains a clinical challenge with generally dismal prognosis. Allogeneic stem-cell transplantation using sequential conditioning ("FLAMSA"-like) has shown promising results in relapsed/refractory acute myeloid leukemia, but little is known about its efficacy in RR-ALL. We identified 115 patients (19-66 years) with relapsed (74%) or primary-refractory (26%) ALL allografted from matched related (31%), matched unrelated (58%), or haploidentical donor (11%). Median follow-up was 37 (13-111) months. At day 100, cumulative incidences of grade II-IV/III-IV acute graft-versus-host-disease (GVHD) were 30% and 17%, respectively. Two-year cumulative incidence of chronic GVHD was 25% with 11% extensive cases. Two-year relapse incidence (RI) was 45%, non-relapse mortality was 41%. Two-year leukemia free survival (LFS) was 14%, overall survival (OS) 17%, and GVHD relapse-free survival (GRFS) was 14%. In multivariable analysis, Karnofsky score <90 negatively affected RI, LFS, OS, and GRFS. Conditioning with chemotherapy alone, compared with total body irradiation (TBI) negatively affected RI (HR = 3.3; p = 0.008), LFS (HR = 1.94; p = 0.03), and OS (HR = 2.0; p = 0.03). These patients still face extremely poor outcomes, highlighting the importance of incorporating novel therapies (e.g., BITE antibodies, inotuzumab, CAR-T cells). Nevertheless, patients with RR-T-cell ALL remain with an unmet treatment need, for which TBI-based sequential conditioning could be one of few available options.

AB - Treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) remains a clinical challenge with generally dismal prognosis. Allogeneic stem-cell transplantation using sequential conditioning ("FLAMSA"-like) has shown promising results in relapsed/refractory acute myeloid leukemia, but little is known about its efficacy in RR-ALL. We identified 115 patients (19-66 years) with relapsed (74%) or primary-refractory (26%) ALL allografted from matched related (31%), matched unrelated (58%), or haploidentical donor (11%). Median follow-up was 37 (13-111) months. At day 100, cumulative incidences of grade II-IV/III-IV acute graft-versus-host-disease (GVHD) were 30% and 17%, respectively. Two-year cumulative incidence of chronic GVHD was 25% with 11% extensive cases. Two-year relapse incidence (RI) was 45%, non-relapse mortality was 41%. Two-year leukemia free survival (LFS) was 14%, overall survival (OS) 17%, and GVHD relapse-free survival (GRFS) was 14%. In multivariable analysis, Karnofsky score <90 negatively affected RI, LFS, OS, and GRFS. Conditioning with chemotherapy alone, compared with total body irradiation (TBI) negatively affected RI (HR = 3.3; p = 0.008), LFS (HR = 1.94; p = 0.03), and OS (HR = 2.0; p = 0.03). These patients still face extremely poor outcomes, highlighting the importance of incorporating novel therapies (e.g., BITE antibodies, inotuzumab, CAR-T cells). Nevertheless, patients with RR-T-cell ALL remain with an unmet treatment need, for which TBI-based sequential conditioning could be one of few available options.

U2 - 10.1038/s41409-019-0702-2

DO - 10.1038/s41409-019-0702-2

M3 - SCORING: Journal article

C2 - 31562398

VL - 55

SP - 595

EP - 602

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -